Meeting
2022 ASCO Annual Meeting
Assessing eligibility for non-intensive chemotherapy (IC) randomized clinical trials (RCT) in patients (pts) with newly diagnosed (ND) AML from the Connect Myeloid Disease Registry.
Authors
Harry Paul Erba
Duke University, Durham, NC
Harry Paul Erba , Daniel Aaron Pollyea , Mikkael A. Sekeres , Guillermo Garcia-Manero , Karen Seiter , Irene DeGutis , Pavel Kiselev , Ali McBride , Edward Yu , Gail J. Roboz
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Track
Hematologic Malignancies
Sub Track
Acute Leukemia
Clinical Trial Registration Number
NCT01688011
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 7029)
DOI
10.1200/JCO.2022.40.16_suppl.7029
Abstract #
7029
Poster Bd #
260
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Impact of induction approach on post-stem cell transplant (SCT) outcomes in older adults with newly diagnosed acute myeloid leukemia (AML).
First Author: Faustine Ong
Poster
2022 ASCO Annual Meeting
Oral azacitidine plus venetoclax in patients with relapsed/refractory or newly diagnosed acute myeloid leukemia: The phase 1b OMNIVERSE trial.
First Author: Farhad Ravandi
Poster
2024 ASCO Annual Meeting
A prospective study of all-trans retinoic acid plus venetoclax and azacitidine in newly diagnosed acute myeloid leukemia.
First Author: Chengyuan Gu
Poster
2024 ASCO Genitourinary Cancers Symposium
Enfortumab vedotin treatment regimens and efficacy in urothelial carcinoma: The Mayo Clinic experience.
First Author: Tara Ballouz